Document is current
Any future updates will be listed below
-
Authors
Andrews, Sophie C.
Curtin, Dylan
Coxon, James P.
Stout, Julie C.
-
Funding
Funding for this research was provided by:
Huntington's Disease Society of America
- License Information
-
More Information
Article History
Received: 18 June 2021
Accepted: 15 December 2021
First Online: 20 January 2022
Competing interests
: Prof. Stout has served on Scientific Advisory Boards (Teva-Australia, Spark Therapeutics), and has performed consulting services for the CHDI Foundation, uniQure NV, and Triplet Therapeutics. She is a director with financial responsibilities for Zindametrix Pty Ltd, which has held contracts in the past 12 months with Vaccinex, uniQure NV, Triplet Therapeutics, and Voyager Therapeutics. Dr. Andrews, Mr. Curtin and Dr. Coxon declare no potential conflict of interest.
